Advanced search
1 file | 219.97 KB Add to list

Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases

BRUNO DE POTTER (UGent) , Gert De Meerleer (UGent) , Wilfried De Neve (UGent) , Tom Boterberg (UGent) , Bruno Speleers (UGent) and Piet Ost (UGent)
(2013) NEUROLOGICAL SCIENCES. 34(5). p.647-653
Author
Organization
Abstract
The aim of the study is to evaluate the efficacy and toxicity of hypofractionated frameless stereotactic radiotherapy (HSRT) with whole brain radiotherapy (WBRT) for the treatment of 1-3 brain metastases. 38 patients with a total of 58 brain metastases were treated at Ghent University Hospital with WBRT (10 x 3 Gy) followed by HSRT (5 x 6 Gy). Patients with RPA class I (n = 8) and II (n = 30) were eligible for HSRT. Acute toxicity was scored with the RTOG toxicity criteria. Response rates were scored every 3 months using the McDonald criteria. Overall survival (OS), brain-specific survival, local and distant brain control were calculated using the Kaplan-Meier method. Patient (age, Karnofsky performance score, KPS, RPA class) and tumor characteristics (number of lesions, extracranial metastases, brain tumor volume, primary cancer status, histology) were tested in univariate and multivariate analysis. Survival at 6 and 12 months was 65 and 35 %, respectively. On univariate analysis KPS < 90, number of lesions, a histologic diagnosis of adenocarcinoma and uncontrolled primary cancer status were statistic significant predictors for poor OS. Four patients (11 %) developed a grade 3 toxicity. Rates of complete remission, partial remission, no change and progressive disease were 30, 40, 23 and 5 %, respectively. Median survival was 7.6 months. The actuarial brain-specific survival was 97 % at 6 months and 91 % at 1 year of follow-up. The 1-year actuarial local and distant brain control was 66 and 75 %, respectively. WBRT ? HSRT is an effective treatment for patients with up to three brain metastases.
Keywords
Brain metastases, HSRT, SINGLE, IMRT, WBRT, ONCOLOGY GROUP RTOG, CONE-BEAM CT, RADIATION-THERAPY, NONINVASIVE FIXATION, CEREBRAL METASTASES, RANDOMIZED-TRIAL, PHASE-II, MANAGEMENT, RADIOSURGERY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 219.97 KB

Citation

Please use this url to cite or link to this publication:

MLA
DE POTTER, BRUNO, Gert De Meerleer, Wilfried De Neve, et al. “Hypofractionated Frameless Stereotactic Intensity-modulated Radiotherapy with Whole Brain Radiotherapy for the Treatment of 1-3 Brain Metastases.” NEUROLOGICAL SCIENCES 34.5 (2013): 647–653. Print.
APA
DE POTTER, BRUNO, De Meerleer, G., De Neve, W., Boterberg, T., Speleers, B., & Ost, P. (2013). Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases. NEUROLOGICAL SCIENCES, 34(5), 647–653.
Chicago author-date
DE POTTER, BRUNO, Gert De Meerleer, Wilfried De Neve, Tom Boterberg, Bruno Speleers, and Piet Ost. 2013. “Hypofractionated Frameless Stereotactic Intensity-modulated Radiotherapy with Whole Brain Radiotherapy for the Treatment of 1-3 Brain Metastases.” Neurological Sciences 34 (5): 647–653.
Chicago author-date (all authors)
DE POTTER, BRUNO, Gert De Meerleer, Wilfried De Neve, Tom Boterberg, Bruno Speleers, and Piet Ost. 2013. “Hypofractionated Frameless Stereotactic Intensity-modulated Radiotherapy with Whole Brain Radiotherapy for the Treatment of 1-3 Brain Metastases.” Neurological Sciences 34 (5): 647–653.
Vancouver
1.
DE POTTER B, De Meerleer G, De Neve W, Boterberg T, Speleers B, Ost P. Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases. NEUROLOGICAL SCIENCES. 2013;34(5):647–53.
IEEE
[1]
B. DE POTTER, G. De Meerleer, W. De Neve, T. Boterberg, B. Speleers, and P. Ost, “Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases,” NEUROLOGICAL SCIENCES, vol. 34, no. 5, pp. 647–653, 2013.
@article{4403786,
  abstract     = {The aim of the study is to evaluate the efficacy and toxicity of hypofractionated frameless stereotactic radiotherapy (HSRT) with whole brain radiotherapy (WBRT) for the treatment of 1-3 brain metastases. 38 patients with a total of 58 brain metastases were treated at Ghent University Hospital with WBRT (10 x 3 Gy) followed by HSRT (5 x 6 Gy). Patients with RPA class I (n = 8) and II (n = 30) were eligible for HSRT. Acute toxicity was scored with the RTOG toxicity criteria. Response rates were scored every 3 months using the McDonald criteria. Overall survival (OS), brain-specific survival, local and distant brain control were calculated using the Kaplan-Meier method. Patient (age, Karnofsky performance score, KPS, RPA class) and tumor characteristics (number of lesions, extracranial metastases, brain tumor volume, primary cancer status, histology) were tested in univariate and multivariate analysis. Survival at 6 and 12 months was 65 and 35 %, respectively. On univariate analysis KPS < 90, number of lesions, a histologic diagnosis of adenocarcinoma and uncontrolled primary cancer status were statistic significant predictors for poor OS. Four patients (11 %) developed a grade 3 toxicity. Rates of complete remission, partial remission, no change and progressive disease were 30, 40, 23 and 5 %, respectively. Median survival was 7.6 months. The actuarial brain-specific survival was 97 % at 6 months and 91 % at 1 year of follow-up. The 1-year actuarial local and distant brain control was 66 and 75 %, respectively. WBRT ? HSRT is an effective treatment for patients with up to three brain metastases.},
  author       = {DE POTTER, BRUNO and De Meerleer, Gert and De Neve, Wilfried and Boterberg, Tom and Speleers, Bruno and Ost, Piet},
  issn         = {1590-1874},
  journal      = {NEUROLOGICAL SCIENCES},
  keywords     = {Brain metastases,HSRT,SINGLE,IMRT,WBRT,ONCOLOGY GROUP RTOG,CONE-BEAM CT,RADIATION-THERAPY,NONINVASIVE FIXATION,CEREBRAL METASTASES,RANDOMIZED-TRIAL,PHASE-II,MANAGEMENT,RADIOSURGERY},
  language     = {eng},
  number       = {5},
  pages        = {647--653},
  title        = {Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases},
  url          = {http://dx.doi.org/10.1007/s10072-012-1091-0},
  volume       = {34},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: